KE / Domain	AOP entity (KE/KER)	Input (manipulation / sample)	Method / Assay (SOP notes)	Output / Measurement	Interpretation / Context fields to capture	Exemplar peer-reviewed manuscripts	Protocol / SOP notes (attach)	S&T considerations (ontology / mapping)
Lung function (decreased) - spirometry	AO: Lung function, decreased (Event 11); adverse outcome at organism level	Human subjects in clinical studies; patients with respiratory disease (asthma, COPD, CF, IPF); population cohorts; environmental or occupational exposure studies	Spirometry for lung function assessment. Standard protocols (ATS/ERS guidelines). Measurements: FEV1 (forced expiratory volume in 1 second), FVC (forced vital capacity), FEV1/FVC ratio, FEF25-75 (forced expiratory flow). Quality control for acceptable and reproducible maneuvers. Pre- and post-bronchodilator testing. Comparison to predicted values based on age, sex, height, ethnicity.	FEV1 (liters and % predicted); FVC (liters and % predicted); FEV1/FVC ratio; FEF25-75; Percent change from baseline; Bronchodilator response; Longitudinal decline rate (mL/year)	Subject demographics (age, sex, height, weight, ethnicity); smoking status; respiratory diagnoses; medication use; exposure history; spirometer type and calibration; technician training; quality control criteria (ATS/ERS acceptability and reproducibility); number of acceptable maneuvers; reference equations used; environmental conditions (temperature, humidity)	Havet et al. (2018). [Lung function assessment in respiratory disease]. Eur Respir J.	Include detailed spirometry protocol following ATS/ERS standards, quality control procedures, calibration routine, acceptable maneuver criteria, reproducibility criteria, interpretation guidelines, reference equation selection, bronchodilator protocol if applicable	Biolink: ClinicalMeasurement; OBI: spirometry assay; Mapping: AO lung function decrease (Event 11); Clinical standard; Reference values; Longitudinal monitoring; Diagnostic and prognostic utility
Lung function and biomarker integration	AO: Lung function, decreased (Event 11); relationship to molecular and cellular biomarkers	Clinical cohorts with lung function measurements; integration with biospecimen collection (blood, sputum, BALF)	Comprehensive lung function testing (spirometry, plethysmography, diffusion capacity). Correlation with molecular biomarkers (inflammatory markers, oxidative stress markers, EGFR pathway components). Multi-omics integration (genomics, transcriptomics, proteomics, metabolomics). Statistical modeling of biomarker-function relationships. Prognostic models for lung function decline.	Spirometry parameters (FEV1, FVC, etc.); Plethysmography (TLC, RV, FRC); DLCO (diffusing capacity); Biomarker levels (cytokines, oxidative stress markers, etc.); Multi-omics signatures; Correlation coefficients; Predictive models for outcomes	Study population; lung function protocols and quality control; biospecimen collection and processing; assay platforms for biomarkers; omics data generation and QC; statistical analysis methods; confounder adjustment; validation cohorts; follow-up duration for longitudinal analyses	Misiukiewicz-Stepien et al. (2025). [Lung function and biomarker relationships in respiratory disease].	Document lung function testing protocols, biospecimen handling, biomarker assay methods, omics protocols, data integration approaches, statistical modeling, quality assurance across all measurements, validation strategies	Biolink: ClinicalMeasurement, IntegratedDataset; OBI: multiple clinical and molecular assays; Mapping: AO lung function decrease, mechanistic biomarkers; Multi-scale integration; Predictive modeling; Precision medicine
Lung function in inflammatory airway disease	AO: Lung function, decreased (Event 11); relationship to airway inflammation and remodeling	Patients with asthma, COPD, or other inflammatory airway diseases; lung function assessment with inflammatory profiling	Lung function testing (spirometry, bronchial challenge tests, FeNO measurement). Inflammatory cell profiling from induced sputum or BALF. Exhaled breath condensate analysis. Serum inflammatory markers. Imaging (chest CT for structural changes). Assessment of exacerbation frequency. Longitudinal monitoring of function and inflammation.	FEV1 and other spirometry parameters; Bronchial hyperresponsiveness (PC20 or PD20); FeNO (fractional exhaled nitric oxide); Sputum or BALF inflammatory cell counts; Inflammatory mediator levels; Exacerbation rates; Imaging findings (airway wall thickness, emphysema)	Patient characteristics; disease diagnosis and phenotype; medication use and adherence; lung function protocols; bronchial challenge methods; sputum induction and processing; FeNO measurement protocol; blood and EBC collection; imaging protocols; longitudinal follow-up schedule; quality control for all methods	Paplinska-Goryca et al. (2025). [Lung function and inflammation in airway disease].	Include lung function testing SOPs, bronchial challenge protocol, FeNO measurement procedure, sputum induction and processing, inflammatory marker assays, imaging protocols, longitudinal study design, quality assurance, data integration methods	Biolink: ClinicalMeasurement; OBI: spirometry, bronchial challenge, inflammatory assays; Mapping: AO lung function decrease, airway inflammation; Disease phenotyping; Exacerbation prediction; Treatment response monitoring
